{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:41:40Z","timestamp":1791243700273,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.02.009","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T16:05:32Z","timestamp":1303142732000},"page":"203-216","source":"Crossref","is-referenced-by-count":194,"title":["Rituximab resistance"],"prefix":"10.1016","volume":"24","author":[{"given":"Andrew R.","family":"Rezvani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2011.02.009_bib1","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","article-title":"Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin\u2019s lymphomas","volume":"23","author":"Khouri","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00277-006-0113-5","article-title":"Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin\u2019s lymphoma","volume":"85","author":"Neumann","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2011.02.009_bib3","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","article-title":"CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes","volume":"14","author":"Hultin","year":"1993","journal-title":"Cytometry"},{"key":"10.1016\/j.beha.2011.02.009_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cyto.990180206","article-title":"Low level CD20 expression on T cell malignancies","volume":"18","author":"Warzynski","year":"1994","journal-title":"Cytometry"},{"key":"10.1016\/j.beha.2011.02.009_bib7","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas","volume":"69","author":"Press","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib9","doi-asserted-by":"crossref","first-page":"42427","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2011.02.009_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002510050412","article-title":"Mice carrying a CD20 gene disruption","volume":"48","author":"O\u2019Keefe","year":"1998","journal-title":"Immunogenetics"},{"key":"10.1016\/j.beha.2011.02.009_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1074\/jbc.273.1.344","article-title":"Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment","volume":"273","author":"Deans","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2011.02.009_bib12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1194\/jlr.E600002-JLR200","article-title":"Rafts defined: a report on the keystone symposium on lipid rafts and cell function","volume":"47","author":"Pike","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.beha.2011.02.009_bib13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1074\/mcp.M800515-MCP200","article-title":"Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma","volume":"8","author":"Boyd","year":"2009","journal-title":"Mol Cell Proteom"},{"key":"10.1016\/j.beha.2011.02.009_bib14","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1158\/0008-5472.CAN-07-5601","article-title":"GM1 expression of non-Hodgkin\u2019s lymphoma determines susceptibility to rituximab treatment","volume":"68","author":"Meyer zum B\u00fcschenfelde","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib16","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2011.02.009_bib18","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib19","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1158\/1078-0432.CCR-08-0745","article-title":"A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma","volume":"14","author":"Racila","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","article-title":"Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance","volume":"21","author":"Bannerji","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib21","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"van der Kolk","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.02.009_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib24","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib26","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1080\/10428190903128660","article-title":"Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma","volume":"50","author":"Weng","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2011.02.009_bib28","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2003-07-2548","article-title":"Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia","volume":"103","author":"Farag","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beha.2011.02.009_bib30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib31","first-page":"7170","article-title":"Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways","volume":"60","author":"Mathas","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib33","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.leu.2402559","article-title":"CD20-induced B cell death can bypass mitochondria and caspase activation","volume":"16","author":"van der Kolk","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.02.009_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.beha.2011.02.009_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2003-06-1901","article-title":"Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma","volume":"103","author":"Zhao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib37","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2 \u2013 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1023\/A:1015463811683","article-title":"Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? (Review)","volume":"22","author":"Selenko","year":"2002","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib39","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenko","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.02.009_bib40","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma (Rapid Communication)","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib41","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib42","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib43","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib44","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib45","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Part 1","key":"10.1016\/j.beha.2011.02.009_bib46","first-page":"574s","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib47","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors (Review)","volume":"40","author":"Fishelson","year":"2003","journal-title":"Mol Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2011.02.009_bib50","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib51","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/eji.200425920","article-title":"Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59","volume":"35","author":"Ziller","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib52","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","article-title":"In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab","volume":"67","author":"Macor","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1349-7006.2006.00139.x","article-title":"Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab","volume":"97","author":"Terui","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.beha.2011.02.009_bib54","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.02.009_bib55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1749-6632.2009.04803.x","article-title":"Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement\/rituximab interactions & clinical results in refractory CLL","volume":"1173","author":"Klepfish","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.beha.2011.02.009_bib56","article-title":"Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia","author":"Xu","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beha.2011.02.009_bib57","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pmed.0050064","article-title":"Statins impair antitumor effects of rituximab by inducing conformational changes of CD20","volume":"5","author":"Winiarska","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.beha.2011.02.009_bib58","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2009-01-200469","article-title":"Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib59","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib60","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","article-title":"Rituximab-mediated cell signaling and chemo\/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions","volume":"15","author":"Vega","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib61","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","article-title":"Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0609.2003.00007.x","article-title":"Loss of CD20 expression in relapsed lymphomas after rituximab therapy","volume":"70","author":"Haidar","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2011.02.009_bib63","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib64","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-08-1403","article-title":"Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin\u2019s lymphoma","volume":"15","author":"Terui","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib65","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib66","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.4049\/jimmunol.179.6.4263","article-title":"Rituximab\u2013CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models","volume":"179","author":"Li","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib67","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.4049\/jimmunol.181.4.2916","article-title":"Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib68","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2011.02.009_bib69","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","article-title":"Tumor burden influences exposure and response to rituximab: pharmacokinetic\u2013pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20","volume":"113","author":"Dayde","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib70","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2125.2009.03494.x","article-title":"Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin\u2019s lymphoma","volume":"68","author":"Ternant","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beha.2011.02.009_bib71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbrc.2009.09.059","article-title":"Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation","volume":"390","author":"Sugimoto","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.beha.2011.02.009_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2010.157","article-title":"HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells","author":"Shimizu","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.02.009_bib73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.02.009_bib74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","article-title":"Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab","volume":"134","author":"Wanner","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.02.009_bib75","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib76","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2009-09-244129","article-title":"Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity","volume":"115","author":"Bil","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Pro","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.02.009_bib78","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1080\/17402520500182329","article-title":"Concurrent administration of granulocyte colony-stimulating factor or granulocyte\u2013monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model","volume":"46","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2011.02.009_bib79","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2402995","article-title":"Treatment of relapsed B-cell non-Hodgkin\u2019s lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy","volume":"17","author":"van der Kolk","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.02.009_bib80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.exphem.2007.08.012","article-title":"NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma","volume":"36","author":"Moga","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2011.02.009_bib81","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-06-1571","article-title":"A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin\u2019s lymphoma","volume":"12","author":"Khan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib82","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-06-1860","article-title":"Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab","volume":"13","author":"Berdeja","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib83","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.2009.07773.x","article-title":"Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma","volume":"146","author":"Friedberg","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.02.009_bib84","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1182\/blood-2008-08-172296","article-title":"Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies","volume":"113","author":"Gertner-Dardenne","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib85","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib86","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib87","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-07-6663","article-title":"Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2011.02.009_bib88","first-page":"687","article-title":"Ofatumumab, a human Mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC","volume":"114","author":"Craigen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib89","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib90","first-page":"385","article-title":"Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma","volume":"114","author":"Hagenbeek","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2011.02.009_bib91","first-page":"369","article-title":"High activity of single-agent ofatumumab, a novel CD-20 monoclonal antibody, in fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia, regardless of prior rituximab exposure","volume":"94","author":"Wierda","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.02.009_bib92","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beha.2011.02.009_bib93","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib94","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure\u2013function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody [Erratum appears in Blood. 2009 May 21;113(21):5368]","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib95","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib96","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.V112.11.234.234","article-title":"A phase I\/II study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ malignant disease","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.02.009_bib98","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in Fc\u03b3RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.02.009_bib99","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3324\/haematol.10327","article-title":"FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma","volume":"92","author":"Mitrovic","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.02.009_bib100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1179\/joc.2007.19.3.315","article-title":"The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms","volume":"19","author":"Galimberti","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.beha.2011.02.009_bib101","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin\u2019s lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.02.009_bib102","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-03-272765","article-title":"Effect of FCGR2A and FCGR3A variants on CLL outcome","author":"Dornan","year":"2010","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T10:20:25Z","timestamp":1592475625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000272"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.02.009","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}